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de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Barcelona, SpainHepatitis C virus (HCV) infection recurs universally after liver indication for liver transplantation (LT). Unfortunately, HCV
transplantation (LT) and ﬁbrosis progression is accelerated in
the graft. Retransplantation (RT) is the only therapeutic option
to achieve long-term survival in patients with decompensated
cirrhosis after LT. Patient and graft survival rates after RT are infe-
rior to those after primary LT. It is generally accepted that severe
hepatitis C recurrence (cholestatic hepatitis) and forms with
rapid ﬁbrosis progression have a poor survival after RT. However,
it is not clear whether rapid ﬁbrosis progression in the ﬁrst graft
will be followed by the same rate of ﬁbrosis progression in the
second graft. The use of prognostic scores as screening tools has
shown an improvement in survival in HCV-infected patients after
RT, reaching similar survival rates as those obtained in non HCV-
infected patients. Moreover, these scores can identify candidates
with a high risk of mortality in whom the use of a new organ
would be unreasonable. Prevention of severe hepatitis C recur-
rence could be the ﬁrst step to avoid RT. Thus, antiviral treatment
on the waiting list (if possible) and early identiﬁcation and treat-
ment of patients with severe hepatitis C recurrence may be a
good strategy to avoid RT. In addition, active management of fac-
tors which can accelerate ﬁbrosis progression (donor age, post-
transplant diabetes, high dose of corticosteroids) might reduce
the incidence of severe forms of hepatitis C recurrence.
 2010 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver.Retransplantation in HCV-infected patients: general
considerations
Hepatitis C virus (HCV) infection has become the most common
cause of cirrhosis and hepatocellular carcinoma in the Western
world. End-stage liver disease due to HCV-infection is the leadingJournal of Hepatology 20
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response.infection recurs universally after LT in patients with detectable
HCV RNA at the time of transplantation [1]. Fibrosis progression,
cirrhosis development, and clinical decompensation occur more
rapidly in HCV-infected liver transplant recipients than in immu-
nocompetent patients [2]: whereas the median interval from
infection to cirrhosis is around 9.5 years in LT recipients, the
same interval is around 30 years in immunocompetent patients.
Cirrhosis develops in around one-third of HCV-infected patients
during the ﬁrst 5 years after LT [3]. In addition, a small number
of individuals (2–5%) develop ﬁbrosing cholestatic hepatitis
(FCH), a severe form of hepatitis C recurrence characterized by
cholestatic hepatitis, hepatocyte ballooning, and perisinusoidal
ﬁbrosis leading to graft failure within a few months after LT
[4]. As a consequence, hepatitis C recurrence is the primary cause
of graft loss and reduction in patient survival in transplant pro-
grams in which HCV-infection is the main indication for LT [5].
The prognosis of patients once graft cirrhosis is established is
poor and when graft failure occurs, retransplantation (RT) is the
only therapeutic option offering a chance for long-term survival.
Berenguer et al. [2] found that patients with clinically compen-
sated cirrhosis achieved a 1-year survival rate of 74%. However,
once patients developed clinical decompensation, survival
decreased to 41% at 1 year and approximately 10% at 3 years.
It is generally accepted that progression to cirrhosis is faster
after RT than after primary LT, particularly in patients with severe
hepatitis C recurrence (cholestatic hepatitis and graft failure
within the ﬁrst year). Patient and graft survival rates after RT are
inferior to those after primary LT and are associatedwith a greater
cost. Pelletier et al. [6] demonstrated a 30% increase in mortality
for HCV-infected RT recipients (20% for HCV-infected primary LT
[7]). Table 1 shows the liver graft survival rate after LT and after
RTbetween1984and2008 in Spain.Most deaths after RT are, how-
ever, not related to hepatitis C recurrence but to post-operative
complications such as bacterial infections. Patients with a more
severe liver disease and poor preoperative clinical conditions have
the highest mortality following RT [8]. Despite liver ﬁbrosis pro-
gression after primary LT has been well characterized [9], studies
assessing this subject after RT are insufﬁcient to draw any solid
conclusions [10,11]. Moreover, other facts may inﬂuence the evo-
lution of HCV-infection after RT. Recent studies have suggested
that the grafting of a new liver may produce signiﬁcant changes
in the HCV quasispecies and may thereby change the severity of
the disease and the susceptibility to antiviral treatment [12,13].10 vol. 53 j 962–970
Table 1. Graft survival of transplanted (LT) and retransplanted (RT) patients from 1984 to 2008 in Spain. Database from ‘‘Organización Nacional de Trasplante” (ONT)
[14].
All etiologies
Mortality risk: 
HR (95%CI), p
LT (n = 14,223)  
2º graft (n = 1,239)  2nd vs. 1st graft: 1.53 (1.38 - 1.7), <0.01
3º graft (n = 127)  3th vs. 1st graft: 
1.85 (1.4 - 2.4), <0.01
HCV-infected patients
LT (n = 4,925)  
2º graft (n = 273)  
3º graft (n = 13)  
1-year 
survival
78.5%
58.1%
49.6%
77.7%
63.4%
69.2%
1-month 
survival
90.3%
76.3%
66.1%
91.9%
83.5%
%001
3-month 
survival
86% 
67.1%
58.3%
87.5%
73.4%
%3.29
3-year 
survival
69.7%
50.9%
44.2%
65.8%
53% 
%3.34
5-year 
survival
64.1%
44.5%
38.3%
57.7%
42.4%
%6.43
10-year 
survival
52.7%
35%
27%
43.8%
32.6%
%6.43 -
15-year 
survival
44.2%
30.2%
%72
34.3%
%02
20-year 
survival
35.6% 
24% 
-
- 
- 
-
LT, liver transplantation; RT, retransplantation; HR, hazard ratio; 95% CI, 95% conﬁdence interval.
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Spanish Transplant Organization showed a worse outcome in
individuals with more than one RT [14] (Table 1). Multivariate
analysis demonstrated a signiﬁcantly higher risk of mortality in
patients who received a second [HR: 1.53 (95% IC: 1.38–1.7)
p <0.01] or third graft [HR: 1.85 (95% IC: 1.4–2.4) p <0.01] as com-
pared to the ﬁrst transplant [15]. However, Akpinar et al. [16],
evaluated 2527 LT between 1987 and 2008. Two hundred and
thirty-ﬁve (9%) patients received two grafts; 32 (1.2%) three; ﬁve
(0.2%) four; and two (0.01%) ﬁve grafts. Patients who underwent
more than one RT had a survival rate of 72%, 56%, and 50% at 1, 5,
and 10 years, respectively. There were no statistically signiﬁcant
differences in survival between these patients and those who
underwent one RT, concluding that multiple RT can be safely
performed.Is HCV-infection an independent risk factor for mortality after
retransplantation?
The main causes of liver graft failure are primary non-function
(PNF), hepatic artery thrombosis (HAT), chronic rejection, and
recurrence of viral or autoimmune disease. RT is performed at
different times depending on the etiology of graft failure: PNF
requires RT during the ﬁrst days, whereas HAT may result in
urgent or delayed RT (the latter when secondary ischemic cho-
langitis is the main complication). Chronic rejection and recur-
rence of viral or autoimmune disease are indications of elective
RT. In general, there are no concerns regarding the use of a liver
graft for RT in emergency situations (such as PNF or HAT) but
elective RT (particularly for HCV recurrence) is much more con-
troversial. Whereas some studies do not clearly identify HCV
recurrence as an independent predictive factor of mortality after
RT [17–22], other recent studies [6,23–26] seem to indicate a
poorer prognosis in RT of HCV-infected patients (Tables 2 and 3).
Studies evaluating early post-transplant variables did not ﬁnd
HCV-infection to be an independent predictor of mortality after
RT [17–22]. The University of Pittsburgh [17] analyzed 418
(17.6%) patientswhounderwentRT out of 2376 LT performed from
1987 to 1993. The 1- and 5-year graft survival after RT was signif-
icantly lower than that of primary LT (50% and 35%, respectively).
The leading causes of graft failure after RT were sepsis (44%) and
ischemic injury-PNF (12%). The variables associated with graftJournal of Hepatology 201failure after RT were donor and recipient age, female donor sex,
the need formechanical ventilation, renal failure, high levels of bil-
irubin and immunosuppression with cyclosporine.
Some studies have suggested HCV-infection as a risk factor of
mortality [25–28]. Rosen et al. [27] analyzed 1356 patients who
underwent RT from the United Network for Organ Sharing
(UNOS) from 1990 to 1996. Recipient age, bilirubin and creatinine
levels, etiology of graft failure and UNOS status (intensive care,
hospitalization, medical care or stable at home) were indepen-
dent predictors of poor outcome after RT. Hepatitis C and donor
age were associated with a poor prognosis on univariate analysis,
but neither had enough power to be included in a predictive
model. Similarly, Ghabril et al. [28] have recently evaluated
1034 HCV-infected patients and 1249 non-HCV-infected patients
who underwent RT between 1994 and 2005. Patient and graft
survival were signiﬁcantly lower for HCV-infected compared to
non-HCV-infected patients who underwent RT at least 90 days
after primary LT. However, based on multivariate analysis, the
only independent predictors of mortality were recipient age,
model for end-stage liver disease (MELD) >25, RT during the ﬁrst
year after LT, donor age >60 and, a warm ischemia timeP75 min.
Other studies, have clearly identiﬁed HCV-infection as a risk
factor of mortality not only after primary LT but also after RT
[6,23,24]. One of the largest clinical UNOS series with more than
4000 patients who underwent RT from 1988 to 2001 [23] showed
seven risk factors for death after RT: PNF, HCV-infection, donor,
and recipient age, creatinine -serum levels before RT, African-
American race, and UNOS status. Patients with HCV recurrence
were 20% and 30% more likely to lose their graft between 1 and
3 years compared with non-HCV-infected patients. Roayaie
et al. [24] showed that HCV-infected patients undergoing RT
had a signiﬁcantly shorter median survival than those undergo-
ing RT for other chronic reasons of graft loss. However, most
deaths occurred during the ﬁrst 6 months after RT and were
due to sepsis by peritonitis or pneumonia. Similarly, Pelletier
et al. [6] analyzed 1718 RT patients (27% with HCV-infection)
from 1997 to 2002 in the Scientiﬁc Registry of Transplant Recip-
ients database. HCV-infected recipients had a 30% higher risk of
mortality than those without HCV-infection (HR: 1.30; CI 95%:
1.10–1.54; p = 0.002). Most deaths occurred between 3 and
12 months after RT and variables associated with a worse
outcome were donor and recipient age, serum-creatinine level,
presence in the intensive care unit, and HCV-infection.0 vol. 53 j 962–970 963
Table 2. Studies and predictive models in urgent and elective RT.
LT, liver transplantation; RT, retransplantation; HCV, hepatitis C recurrence; HAT, hepatic artery thrombosis; PNF, primary non-function; MV, mechanical ventilation; ELTR,
European Liver Transplant Registry; SRTR, Scientiﬁc Registry of Transplant Recipients database; y, years; d, days; h, hours; m, minutes; R, risk score; INR, international
normalized ratio; UNOS (United Network for Organ Sharing) status, [1 (intensive care unit-bound), 2 (hospitalized), 3 (medical care), 4 (stable a thome)]. HR, hazard ratio;
95% CI, 95% conﬁdence interval. () Liver grafts.
The studies identifying HCV-infection as a risk factor of mortality on multivariate analysis are marked with a star.
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Table 3. Studies and predictive models for RT (excluding patients with graft failure by PNF).
Author 
(year),
[reference]. 
Facciuto et al. 
(2000),  
.]53[
Watt et al. 
(2003),  
[32]. 
Rosen et al.  
(2003),  
[31]. 
e
-
R
R
Roayaie et al. 
(2003),  
[24]. 
- 
Yao et al.  
(2004), 
 [26]. 
Feng et al.  
(2006),  
[37]. 
Northup et al. 
(2007),  
[34]. 
Ghabril et al.  
(2008),  
[28]. 
Period and 
population
1989-1997
(Mt. Sinai)
1996-2002
(UNOS) 
1986-1999
(UNOS, 
European)
1989-2001
(Mt. Sinai)
1988-2002
(Univ. of 
California)
 1998-2002
(SRTR) 
2002-2006
(UNOS) 
1994-2005
(UNOS) 
LT (n) 
964 
HCV 
(n = 414)
22,120
HCV 
(43.2%)
- 
1,738 
HCV 
(n = 646)
1,162 
20,023
HCV 
(1.8%) 
46,982  
RT (n) 
HCV (n) 
48, HCV (n=21) 
Excluded RI <6 m 
)321=n(
2,129, HCV (42.2%)
Excluded RI <30d 
979, HCV (25%) 
Excluded RI <15d 
)361=n(
)24=n(VCH,15
Excluded RI <90d 
)28=n(
40, HCV (20%) 
Excluded RI <90d 
(n = 36)
- 
1,327  
HCV (1.8%) 
2,283, HCV (n = 1034)
RI: <90d, 90-365d,  
d563>
Variables associated 
with worse outcome 
after RT 
Recipient age >50 y, 
creatinine >2 mg/dl and 
use of intraoperative 
platelets. 
Creatinine (mg/dl), 
bilirubin (mg/dl) and 
Prothrombin time (INR).
Recipient age (y),  
RT <60 days after LT, 
creatinine (mg/dl) and 
bilirubin (mg/dl).  
Prothrombin time 
(seconds), donor age 
(y) and HCV-infection.*
Univariate: Hepatic 
encephalopathy, 
creatinine, CTP ≥10
MELD >25, ICU status, 
and HCV-infection.
Multivariate: Hepatic 
encephalopathy. 
Donor: age >40  (y), 
donation after cardiac 
death (DCD), 
split/partial grafts, 
African-American race, 
less height and 
cerebrovascular 
accident (CVA). 
Recipient: cause of 
graft failure. 
Recipient age, MELD > 
25, RI< 1 year, donor 
age >60, a warm 
ischemia time  75 
minutes. 
Predictive 
model 
- 
R = 0.957 x log 
(creatinine) + 
0.378 x log 
(bilirubin) + 
1.120 x log 
(INR). 
R = 10 x [0.0236 
(recipient age) 
+ 0.125 
( Îbilirubin) + 
0.438 (log
creatinine) 
0.234 (RI)]. 
[RI= 0 for 
15-60 d
and 1 for >60d] 
- 
CTP and MELD 
scores. 
RTDRI = DRI + 
[(0.119 if 
biliary) + (0.094 
if recurrent 
disease) + 
(0.063 if 
rejection) + 
(0.187 if 
vascular 
thrombosis) + 
(0.017 if all 
other)]. 
MELD score.  
Survival 
1-y  
survival: 60% 
5-y  
survival: 42% 
MELD> 25 
5-y  
survival 
<60% 
y-1
survival: 
> 20.5: 42%
%57:61
CTP  10, 
MELD > 25 
1-y 
survival:50%,
53% 
5-y 
survival:40%,
47%  
RTDRI > 2.5 
survival 
<53% 
1-y  
survival: 
<70% 
3-y  
survival: 
<59% 
LT, liver transplantation; RT, retransplantation; HCV, hepatitis C recurrence; PNF, primary non-function; RI, retransplant interval; UNOS, United Network for Organ Sharing;
SRTR, Scientiﬁc Registry of Transplant Recipients database; CTP, Child–Turcotte-Pugh; MELD, model for end-stage liver disease; ICU, intensive care unit; RTDRI, Retransplant
Donor Risk Index; y, years; m, months; d, days; INR, international normalized ratio. DRI (Donor Risk Index), exp [(0.154 if 406 age <50) + (0.274 if 50 6 age < 60) + (0.424 if
606 age <70) + (0.501 if 70 6age) + (0.079 if COD = anoxia) + (0.145 if COD = CVA) + (0.184 if COD = other) + (0.176 if race = African-American) + (0.126 if race =
other) + (0.411 if DCD) + (0.422 if partial/split) + (0.066 ((170  height)/10)) + (0.105 if regional share) + (0.244 if national share) + (0.010  cold time)].
The studies identifying HCV-infection as a risk factor of mortality on multivariate analysis are marked with a star.
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[29] established that bilirubin P10 mg/dl, creatinine P2.0 mg/
dl (or creatinine clearance <40 ml/min), recipient age >55, donor
age >40 and early HCV recurrence (cirrhosis <1 year after LT)
were variables associated with a worse outcome after RT. The
worse outcome after RT in cases of early severe hepatitis C recur-
rence has been shown in some studies [28] but may reﬂect the
poor liver function in individuals with cholestatic forms of hepa-
titis C at the time of RT [10].Predictive models of survival following retransplantation
Due to the lack of a clear consensus, different models based on
logistic regression analysis of donor and recipient variables have
been developed to help in the decision-making process of
patients listed for RT. Most predictive models are derived from
retransplanted individuals including urgent (PNF or HAT) and
elective indications for RT [17,20–22,27,30] (Table 2). The ﬁrst
predictive models identiﬁed the need for mechanical ventilation
[17,20], UNOS status [27] and the urgency of RT [22,30] as prog-
nostic factors of mortality. Markmann et al. [20] identiﬁed ﬁve
variables (recipient age P18 years, requirement for preoperative
mechanical ventilation, cold ischemia timeP12 h, creatinine and
bilirubin levels) as independent prognostic values to estimate
patient survival after RT. These authors identiﬁed a subgroup of
patients with a score >2.3 with an expected 1-year survival
<40% in whom RT was not justiﬁed. Recently, Linhares et al.
[30] constructed a model that included recipient age, creatinine,
urgency of RT, and early failure of the initial LT. The 1-, 3-, and 5-
year survival rates reached 85%, 82%, and 77% for scores <24 and
69%, 66%, and 61% for scores 24–32 whereas survival rates for
scores >32 were signiﬁcantly lower (21%, 19%, and 16%).
Hepatitis C recurrence is usually an indication for elective RT.
Therefore, scores used for urgent RT [17,20–22,27,30] are proba-
bly not useful in candidates with hepatitis C (Table 2). Scores
more commonly used in this setting include: (1) the Rosen score
[31], (2) the MELD score [26,28,32], (3) the Child–Turcotte-Pugh
score [25,26,33], and (4) the Donor Risk Index (DRI) [34] (Table 3).
The variables with the highest impact on survival after RT are
serum bilirubin [17,18,20–22,27,31,32] and creatinine
[6,17,18,20–23,26,27,30–32,35] (both included in the MELD and
Rosen scores). Rosen et al. [31] validated a model based on reci-
pient age, bilirubin, creatinine and retransplant interval time (RI)
in patients who underwent RT from the UNOS registry (n = 773)
in ﬁve European and one Australian center (n = 206). The patients
with an R score 616 had the best 1- and 3-year survival (75% and
70%) while in patients with an R score P20.5, survival was only
42% and 38%, respectively (Table 3). The ﬁrst study evaluating
the MELD score in RT candidates was published in 2003 [32]
including a total of 22,120 primary LT (43.2% with HCV-infection)
and 2129 RT (42.2% with HCV-infection) from 1996 to 2002.
Patients with malignancy or those who underwent RT within
30 days after LT were excluded. Survival after RT did not differ
for HCV-infected patients in comparison with other causes of
elective RT (metabolic, genetic, alcohol, cryptogenetic, primary
biliary cirrhosis, primary sclerosing cholangitis), and only auto-
immune hepatitis and hepatitis B showed a higher survival. In
contrast, a MELD >25 was a clear risk factor of short-term survival
after RT, suggesting that liver and kidney function (MELD score)
could be more important than etiology in elective RT. Bussutil966 Journal of Hepatology 201and Ghobrial [21] elaborated a model to calculate survival in
patients with LT or RT based on recipient and donor age, creati-
nine, bilirubin, prothrombin time, and warm and cold ischemia
times. Three years later, the same authors [36] substituted the
preoperative serum creatinine, bilirubin, and prothrombin values
for the MELD score and included the time between ﬁrst and sec-
ond transplantation. These authors reported a 1-year survival
beneﬁt >65% in 30- to 40-year-old recipients with any MELD
score and in 50-year-old candidates with a MELD 624. They rec-
ommended avoiding RT in older recipients or those with a MELD
>28. Another interesting model is the Donor Risk Index (DRI)
developed by Feng et al. [37]. These authors identiﬁed seven
donor variables that independently predicted a higher risk of
graft failure after RT: donor age >40 years (particularly
>60 years), donation after cardiac death, split/partial grafts, Afri-
can-American race, low height, and cerebrovascular accident.
Northup et al. [34] recently evaluated the DRI in 1327 patients
who underwent RT. The authors showed that the addition of
the cause of graft failure to the DRI signiﬁcantly increased its pre-
dictive value.Improving survival in HCV-infected patients after RT
Severe hepatitis C recurrence is one of the leading indications for
RT. RT for this indication ranges from 3.6% to 44% [15] and has
shown an increase during recent years. In Spain, 14,223 patients
underwent LT between 1984 and 2008 and 4925 (34.6%) had
HCV-infection. This ﬁgure is probably higher since most patients
with hepatocellular carcinoma (HCC) are infected with the HCV.
Among all the transplanted patients, 1410 (9%) underwent RT
and in 438 (31%) the indication was severe hepatitis C recurrence
[14].
One of the most difﬁcult issues in RT is to determine the opti-
mal timing to perform elective RT. This may be explained by the
high number of variables that should be taken into account (as
mentioned above), such as liver function, donor characteristics,
and post-operative complications [38]. Recent studies using some
of the above described prognostic scores as screening tools have
shown similar survival rates in HCV-infected compared to non-
HCV-infected patients [33,39] (Table 4). McCashland et al. [39]
did not ﬁnd any differences in survival between HCV- and non-
HCV-infected patients undergoing RT when the selection was
performed using the Rosen [31] and Markmann [20] scores. The
1- and 3-year survival in HCV-infected patients and non-HCV-
infected patients who underwent RT was similar. The 1- and 3-
year survival after RT was 69% and 49% for HCV-infected patients
and 73% and 55% for non-HCV-infected individuals. Thus, an
appropriate selection of candidates for RT results in acceptable
outcomes. Recently, Marti et al. [33] evaluated 108 patients
who underwent non-urgent RT adopting the Rosen score. Only
HCV-infected patients who developed cirrhosis P3 years after
primary LT underwent RT. Applying these selection criteria, the
authors did not ﬁnd signiﬁcant differences in survival after RT
at 1, 5, and 10 years between patients with hepatitis C recurrence
(70%, 57%, and 57%, respectively) and all other causes (72%, 50%,
and 45%, respectively).
Although the Rosen [31] and Markmann [20] prognostic mod-
els have been validated, the pros and cons of one model versus
the other have not been investigated and more studies evaluating
the utility of MELD score to select RT candidates are needed0 vol. 53 j 962–970
Table 4. Studies in HCV-infected patients using prognostic scores as screening tools for RT.
McCashland et al. 
(2007),  
[39]. 
Marti et al.  
(2008), 
[33]. 
116
108 
.S.U11
centers 
elgniS
European 
center
[20]
Markmann model
 2.3 
Rosen model
[31]
≤ 20 5.
Rosen model
[31]
 20.5 
Recipient < 18-y 
RT < 90d after LT
Recipient < 18-y 
FCH 
Cirrhosis < 3-y 
after LT
Etiologies 
(1) Recurrent HCV (n = 43) 
(2) Non          (n = 73)-HCV  
Time period
(1) 1988          (n = 53)-1997
(2) 1997           (n = 55)-2006  
Indication  
(1) Urgent: <7d
after LT (n = 24)
(2) Semi-urgent: 8-90d
after LT (n = 14)
(3) Elective: > 90d 
)07=n(TLretfa
Global (ns) 
(1) 49% 
(2) 55% 
R< 16 (ns) 
(1) 53% 
(2) 70% 
R 16- 20.5 (ns)  
(1) 21% 
(2) 43% 
Global  54.4%
Time period
(p<0.05)
(1) 45%
(2) 69%
Indication (ns)
(1) 58% 
(2) 76% 
(3) 51% 
1996-
2004
1988-
2006
RT oP pulation Screening tools Exclusion criteria Group of  RT patients 3-year 
Survival
Time 
period
Author 
(year),
[reference].
RT noitalupoP Screening tools Exclusion criteria Group of 
RT patients
Global (ns) 
(1) 69% 
(2) 73% 
R< 16 (ns) 
(1) 74% 
(2) 76% 
R 16- 20.5 (ns)
(1) 42% 
(2) 72% 
Global  70%
Time period 
(p<0.05)
(1) 66%
(2) 76%
Indication (ns)
(1) 62%
(2) 86%
%17)3(
1-year 
Survival
1-year 
Survival
5-year 
Survival
Time 
period
Author 
(year),
[reference].
RT, retransplantation; d, days; y, years; ns, not signiﬁcantly different; FCH, ﬁbrosing cholestatic hepatitis; d, days; LT, liver transplantation.
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cation of RT for HCV recurrence at an early stage could improve
survival.Considerations in retransplantation of HCV-infected patients
Several considerations may inﬂuence (directly or not) the deci-
sion to indicate RT in HCV recurrence: donor shortage, the efforts
and resources utilized in LT, and in some cases, the emotional
relationship established with the patient after the ﬁrst LT. How-
ever, in order to maintain a principle of equity, it seems reason-
able to indicate RT in HCV-infected patients if a minimal
probability of survival of 50–60% at 1 year is reached. As men-
tioned above, bilirubin [17,18,20–22,27,31,32] and creatinine
[6,17,18,20–23,26,27,30–32,35] levels are essential for discrimi-
nating RT candidates. Other variables such as center experience
[40] or the age of the recipient [41] are more controversial. The
use of prognostic models in HCV-infected patients can identify
recipients with an acceptable prognosis after RT and their use
should be recommended in the evaluation of RT candidates
[33,39]. As shown above, several models have demonstrated a
subgroup of patients with a high risk of death after RT: candidates
with a Markmann score >2.3 [20], Rosen scoreP20.5 [31], Child-
Pugh scoreP10 [26], MELD >25 [32] or a Linharesmodel >36 [30].
The use of a new organ in these candidates seems unreasonable.
The increasing number of patients on the waiting list has
prompted the use of extended criteria donors (ECD) [38]. The pre-
cise deﬁnition of ECD remains elusive but this deﬁnition includesJournal of Hepatology 201grafts with characteristics that can produce initial poor function
or graft failure after transplantation [42]. Some authors have
shown similar survival rates using ECD in patients with HCV-
infection compared to other grafts. Northup et al. [34] showed
that the use of ECD in patients with HCV-infection did not incur
a worse survival. Actually, it has been suggested that the risk/
beneﬁt ratio is clearly better when using ECD in high-risk recip-
ients (high MELD score) [45]. However, the use of ECD for RT is
controversial for different reasons: (1) long-term data of LT and
RT with ECD are lacking, (2) recipients of ECD grafts frequently
have sub-optimal characteristics, and (3) the use of these grafts
could be detrimental due to the additive effect of sub-optimal
donors and recipients resulting in a higher mortality. For theses
reasons, some authors do not consider the use of ECD in high-risk
recipients, such as the use of grafts with moderate steatosis in
recipients with a high MELD score [43] or the use of old donors
in HCV recipients [44].Prevention of need for retransplantation
The ﬁrst step to prevent liver RT in HCV-infected patients is to
identify those patients at risk of developing severe hepatitis C
recurrence. It is well known that early histological damage in
protocol liver biopsies correlates with severe hepatitis C recur-
rence and poor long-term outcome after LT [46,47]. The Interna-
tional Liver Transplantation Society Expert Panel [29] established
the administration of antiviral treatment if moderate to severe
(grade 3 to 4) inﬂammation or signiﬁcant ﬁbrosis (stage 2) was0 vol. 53 j 962–970 967
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present in protocol liver biopsies. Interestingly, the hepatic
venous pressure gradient (HVPG) has demonstrated to be more
accurate than liver biopsy at identifying patients at risk of clinical
decompensation [48,49]. Recently, transient elastography (a non-
invasive method to determine liver stiffness) has been shown to
accurately identify liver ﬁbrosis in LT patients [50,51]. It is there-
fore essential to identify patients who are at risk of progressive
hepatitis C recurrence early after LT, since antiviral treatment
can stabilize liver ﬁbrosis progression and portal pressure [52]
(see below). Thus, antiviral treatment of patients with severe
hepatitis C recurrence or early after RT could have an important
impact on graft and patient survival.
Antiviral treatment of HCV-infection in the transplant setting is
currently based on pegylated interferon and ribavirin. However,
most of the studies published on antiviral efﬁcacy in LT patients
are retrospective, uncontrolled and have a small sample size.
Two recent systematic reviews [53,54] have shown a sustained
virological response (SVR) rate of around 30–40%. The ﬁrst review
[53] of 19 studies from2002 to2007 (16usingpegylated interferon
with ribavirin)with611patients reported a SVRof 30%. The second
review between 1999 and 2008 [54] analyzed only six controlled
studies with 242 patients and reported a median SVR rate of 31%.
Although the rate of viral clearance in the transplant setting is sig-
niﬁcantly lower than in the immunocompetent patients, antiviral
treatment decreases the progression of liver ﬁbrosis [55,56] and
reduces portal pressure [52] particularly in individuals who
achieve SVR. In a recent prospective randomized control study
using pegylated interferon plus ribavirin in HCV-infected patients
who underwent LT, antiviral therapy was the only variable inde-
pendently associated with histological response and was clearly
associated with hemodynamic improvement [52]. The authors
described stabilization and improvement in liver ﬁbrosis and por-
tal pressure even in patients with biochemical response who did
not achieve viral clearance. Importantly, some authors have rec-
ommended the use ofmaintenance therapy tomodulate the sever-
ity of disease progression and prevent graft failure [57]. The long-
term outcome of patients who achieve SVR has recently shown to
improve the natural history of HCV recurrence,with a signiﬁcantly
lower progression to cirrhosis and clinical decompensation and
higher rates of survival compared to non-responders [58,59].
Another strategy to prevent HCV recurrence is the treatment
of HCV-infected patients before LT. Antiviral treatment before
LT has been shown to avoid graft infection in a signiﬁcant propor-
tion of patients [60,61]. However, treatment is usually restricted
to Child-Pugh class A patients (in whom the indication of LT is
HCC) or in selected Child-Pugh class B patients [62]. Regretfully,
this scenario is very unusual in patients who need RT, since most
are in advanced liver failure and are not good candidates for anti-
viral treatment due to the high risk of bacterial infection (partic-
ularly spontaneous bacterial peritonitis) [62].
Other important issues could affect the natural history of HCV
recurrence. Early treatment of biliary complications [63] and
intensive treatment and control of diabetes mellitus [64] may
have a beneﬁcial inﬂuence on HCV progression after LT. Donor
age [44] is a well known factor affecting long-term outcome in
HCV recipients and efforts are made to match donors and recip-
ients without disturbing the equity principle of recipients with
other etiologies. At present, there is no evidence in favor of the
use of a particular immunosuppressive regimen [65] to modify
HCV progression after LT, and some reports on the use of a spe-
ciﬁc regime during antiviral treatment are controversial. How-968 Journal of Hepatology 201ever, active management of those factors which can accelerate
ﬁbrosis progression (avoidance of high dose corticosteroids, pre-
vention and early treatment of diabetes) might reduce the inci-
dence of severe forms of hepatitis C recurrence.
In summary, the best approach to prevent RT in HCV-infected
patients is to administer antiviral treatment to patients at high
risk of severe hepatitis C recurrence (i.e. those with signiﬁcant
ﬁbrosis or portal hypertension soon after transplantation). Since
antiviral therapy only eradicates HCV-infection in around one-
third of treated individuals, RT is the only choice for individuals
progressing to graft cirrhosis. Regretfully, survival after RT is sig-
niﬁcantly lower compared to survival after primary liver trans-
plantation. In the current era of donor shortage, RT should be
indicated only in patients with a reasonable survival probability.
In this setting, the use of well-validated predictive scores is help-
ful and should be implemented in liver transplant programs.
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